Recruiting Multiple Myeloma Studies in Heidelberg
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma....
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM)....
About Multiple Myeloma Clinical Trials in Heidelberg
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 2 multiple myeloma clinical trials recruiting participants in Heidelberg, VICTORIA. These studies are seeking a combined 88 participants. Research is being sponsored by Heidelberg Pharma AG, Janssen Research & Development, LLC. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Heidelberg — FAQ
Are there multiple myeloma clinical trials in Heidelberg?
Yes, there are 2 multiple myeloma clinical trials currently recruiting in Heidelberg, VICTORIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Heidelberg?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Heidelberg research site will contact you about next steps.
Are clinical trials in Heidelberg free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Heidelberg studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 2 active trials in Heidelberg are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov